Baxano Surgical Announces the Launch of iO-Tome(TM), A Novel Minimally Invasive Facetectomy Instrument

RALEIGH, N.C., Oct. 1, 2013 (GLOBE NEWSWIRE) -- Baxano Surgical, Inc. (Nasdaq:BAXS), a medical device company focused on designing, developing and marketing minimally invasive products to treat degenerative conditions of the lumbar spine, today announced the launch of a novel disposable facetectomy instrument called iO-Tome that allows surgeons to perform rapid and safe facetectomies when performing certain interbody spinal fusion procedures.

The iO-Tome device utilizes Baxano Surgical's iO-Flex® technology to deliver a new MicroBlade Shaver® design configured to rapidly and precisely remove the facet joint.

Robert E. Isaacs, MD, a neurosurgeon at Duke University Medical Center, who has been an early evaluator of the instrument, stated "The iO-Tome device has substantially decreased the time I spend performing a facetectomy in my tube-based TLIF procedures."

"After a strong limited market release over the past six months, we are very optimistic about the launch of iO-Tome," stated Ken Reali, President and CEO of Baxano Surgical. "Strategically iO-Tome fits well with our AxiaLIF® Plus, VEO® and iO-Flex products allowing us to deliver a differentiated and expanded portfolio of products to MIS spine surgeons."

iO-Tome, along with Baxano Surgical's other products, will be showcased at upcoming spine society conferences this fall, including NASS (North American Spine Society), CNS (Congress of Neurosurgeons) and SMISS (Society for Minimally Invasive Spine Surgeons).

About Baxano Surgical, Inc.

Baxano Surgical, Inc. is a medical device company focused on designing, developing, and marketing minimally invasive products to treat degenerative conditions of the spine affecting the lumbar region. Baxano Surgical currently markets the AxiaLIF family of products for single and two level lower lumbar fusion, the VEO lateral access and interbody fusion system, the iO-Flex system, a proprietary set of flexible instruments used by surgeons during spinal decompression procedures and the iO-Tome instrument, which rapidly and precisely removes bone, specifically the facet joints, which is commonly performed in spinal fusion procedures. Baxano Surgical was founded in May 2000 and is headquartered in Raleigh, North Carolina. For more information, visit www.baxanosurgical.com.

AxiaLIF, VEO, iO-Flex and MicroBlade Shaver are registered trademarks of Baxano Surgical.

Forward Looking Statements

This press release includes statements that are based on our current beliefs and assumptions. These statements constitute "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, the pace of adoption of our product technology by spine surgeons, the outcome of coverage and reimbursement decisions by the government and third party payors, the success of our continuing product development efforts, the effect on our business of existing and new regulatory requirements, our ability to raise additional capital, our ability to comply with our settlement agreement and Corporate Integrity Agreement with certain entities of the U.S. government, stockholder class action lawsuits, and other economic and competitive factors. For a discussion of the most significant risks and uncertainties associated with Baxano Surgical's business, please review the Company's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2012 and subsequent reports. You are cautioned not to place undue reliance on these forward looking statements, which are based on Baxano Surgical's expectations as of the date of this press release and speak only as of the date of this press release. We undertake no obligation to publicly update or revise any forward looking statement, whether as a result of new information, future events or otherwise.

CONTACT: Investors: Westwicke Partners Mark Klausner, 443-213-0501 baxanosurgical@westwicke.comSource:Baxano Surgical, Inc.